GHRP-2 vs GHRP-6: A Research Comparison

GHRP-2 and GHRP-6 are the two most often compared members of the growth hormone releasing peptide family. Labs working on the growth hormone axis regularly choose between them. Both are synthetic peptides of six amino acids. Both activate the growth hormone secretagogue receptor, GHS-R1a. Yet the literature describes them differently on potency. They also differ on the secondary ghrelin-type signaling seen in research models. This comparison sets out the sequence chemistry, receptor pharmacology, and reported profile differences behind that choice. It stays strictly within a lab research context.

How are GHRP-2 and GHRP-6 related?

GHRP-2 and GHRP-6 are sibling peptides that share most of their sequence. GHRP-6 is the older of the two and the more fully studied.

GHRP-6 specs:

• Sequence: His-D-Trp-Ala-Trp-D-Phe-Lys-NH2
• Molecular formula: C46H56N12O6
• Molecular weight: about 873.01 g/mol
• CAS number: 87616-84-0
• Also designated SKF-110679

It was one of the first growth hormone secretagogues to be widely studied. So it is the reference compound that later peptides in the class are measured against.

GHRP-2 is the structurally modified sibling. Its specs:

• Sequence: D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH2
• Molecular formula: C45H55N9O6
• Molecular weight: about 817.97 g/mol
• CAS number: 158861-67-7
• Generic name pralmorelin, also designated KP-102 and GPA-748

Both peptides share the Ala-Trp-D-Phe-Lys-NH2 stretch at positions three to six. GHRP-2 swaps in D-Ala and D-2-naphthylalanine for the histidine and D-tryptophan at the start of GHRP-6.

That shared end region explains why both bind the same receptor. The swapped starting residues are the usual structural reason given for their profile differences. Each molecule is covered in detail in the GHRP-2 mechanism of action and GHRP-6 mechanism of action articles.

What receptor pharmacology do GHRP-2 and GHRP-6 share?

Both peptides are agonists at GHS-R1a, the G-protein-coupled receptor for natural ghrelin. Neither works through the classic growth hormone releasing hormone (GHRH) receptor.

That is why both are grouped as secretagogues, not GHRH analogues. It is also why studies often pair a GHRP with a GHRH analogue. The pairing probes the two arms of the axis separately.

In both cases, receptor activity couples to Gq/11 signaling. This leads to production of inositol trisphosphate and a rise in calcium inside the cell. These second-messenger steps are studied as drivers of the growth hormone release seen in pituitary cell systems.

In animal models, both peptides are studied for triggering growth hormone release from somatotrophs. They are also studied for how they interact with somatostatin, the signal that holds that release back.

The receptor and early cascade are shared. So much of the study design carries over. Binding assays, calcium flux readouts, and somatotroph culture protocols built for one generally work for the other. That makes the two a useful matched pair.

Where do GHRP-2 and GHRP-6 differ?

The difference shows up after the shared receptor step. GHRP-2 is described as keeping strong growth hormone releasing activity. It shows a changed profile of ghrelin-linked effects.

So GHRP-2 is the more common choice when the question is about growth hormone axis signaling itself. It fits when secondary ghrelin pathway activity would muddy the readout.

GHRP-6, by contrast, stands out in the family for strong ghrelin-mimicking activity. That clear signature is why it is used to study appetite-related signaling and feeding behavior in animal models. It is also why it serves as the reference point for judging the selectivity of newer secretagogues.

• GHRP-2: generally described as more potent for growth hormone axis signaling, with less ghrelin-type secondary signaling in models.
• GHRP-6: the original GHRP, noted for a stronger appetite-signaling effect through ghrelin pathway activity in models.
• Shared: the same GHS-R1a target, Gq/11 coupling, and six-amino-acid class.

This is a difference in the profile reported across preclinical and in vitro work. It is not a claim about any outcome outside those models.

How does selectivity compare with Ipamorelin?

A third peptide makes the selectivity range clearer. Ipamorelin is a selective ghrelin receptor agonist of five amino acids. It is studied in research on growth hormone pulses. It is one residue shorter than either GHRP. It is generally described as the most selective of the three, with limited off-axis signaling reported in models.

Seen as a range, the three line up like this:

• GHRP-6 sits at the least selective end, with the broadest secondary ghrelin pathway signature.
• GHRP-2 sits in the middle.
• Ipamorelin sits at the selective end.

Studies where secondary ghrelin signaling would confound the main readout tend to move along that range toward ipamorelin.

Hexarelin is sometimes added as a fourth comparison. It is studied for receptor pharmacology and cardiac tissue signaling. Panels across several secretagogues are a standard way to map differences in receptor activity and secondary profile.

Which peptide fits which research question?

The choice usually follows from the question being asked, not from any ranking of the compounds.

Some studies focus on growth hormone release from somatotrophs. Others focus on how GHS-R1a interacts with the somatostatin and GHRH systems. For these, GHRP-2 is the more common choice, because secondary signaling is less likely to muddy the result.

Other studies focus on the ghrelin pathway itself, including feeding behavior and energy balance models. For these, GHRP-6 is the standard tool. Its ghrelin-mimicking activity is a feature, not an artifact. It is also the right benchmark arm when the goal is to measure the selectivity of a newer secretagogue.

• Growth hormone axis pharmacology with little secondary confound: GHRP-2, or ipamorelin for greater selectivity.
• Ghrelin pathway and appetite signaling models: GHRP-6.
• Selectivity benchmarking of a newer secretagogue: GHRP-6 as the reference arm.
• Comparative receptor activity panels: both, under matched conditions.

How are GHRP-2 and GHRP-6 supplied, handled, and verified?

Puritide Research supplies both peptides as freeze-dried research-use-only material and does not manufacture them in house. Each comes as a 10mg vial of solid white powder in sealed glass. Each is sourced and third-party tested before release at 99% purity or greater.

Every batch ships with a Certificate of Analysis. It covers:

• Purity by HPLC and reverse-phase chromatography.
• Identity confirmed by mass spectrometry.
• Lot, date, and method details.

Storage guidance is the same for both. Keep each at or below 25 degrees Celsius, sealed, and away from heat, light, and moisture. For long storage, keep the material freeze-dried and chilled or frozen. Hold conditions steady across the study.

For in vitro prep, dissolve in bacteriostatic water and split into single-use aliquots. This limits the repeated freeze-thaw cycles that harm peptides. Follow institutional standard procedures and chemical hygiene plans.

Record lot numbers with storage activity and keep batch records. This supports tracing when results are compared later.

Common research questions

What is the main difference between GHRP-2 and GHRP-6 in research models?

Both are six-amino-acid agonists at GHS-R1a. The most cited difference is in profile. GHRP-2 is described as more potent for growth hormone axis signaling, with less secondary signaling. GHRP-6 shows a stronger appetite-signaling effect through ghrelin pathway activity in research models.

Are GHRP-2 and GHRP-6 interchangeable in GHS-R1a assays?

They share the receptor target and Gq/11 coupling, so assay formats generally carry over between them. But they are not interchangeable as test variables. The difference in secondary signaling is exactly what many comparison studies are set up to measure.

How do both compare with ipamorelin?

Ipamorelin is a selective five-amino-acid agonist at the same receptor. It is generally described as having less off-axis signaling than either GHRP. Labs often pick it when secondary ghrelin pathway activity would confound a growth hormone axis model.

For research use only. GHRP-2 and GHRP-6 are laboratory research compounds, not approved for human or veterinary use. All findings described here come from in vitro assays and animal models and should be read within those experimental settings.